

PHARMACEUTICAL 2022

Greenwich LifeSciences Inc. Rank 15 of 466









PHARMACEUTICAL 2022



RealRate Gi

Greenwich LifeSciences Inc. Rank 15 of 466

The relative strengths and weaknesses of Greenwich LifeSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greenwich LifeSciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 546% points. The greatest weakness of Greenwich LifeSciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 301%, being 223% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	13
Liabilities, Current	385
Liabilities, Non-Current	0
Other Assets	27,204
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	27
Other Revenues	0
Property and Equipment	0
Research and Development	3,560
Selling, General and Administrative Expense	1,038

Output Variable	Value in 1000 USD
Assets	27,217
Liabilities	385
Expenses	4,598
Revenues	0
Stockholders Equity	26,832
Net Income	-4,571
Comprehensive Net Income	-4,571
Economic Capital Ratio	301%

